BR112016012968A2 - Métodos e composições para o tratamento de condições associadas com o envelhecimento - Google Patents

Métodos e composições para o tratamento de condições associadas com o envelhecimento

Info

Publication number
BR112016012968A2
BR112016012968A2 BR112016012968A BR112016012968A BR112016012968A2 BR 112016012968 A2 BR112016012968 A2 BR 112016012968A2 BR 112016012968 A BR112016012968 A BR 112016012968A BR 112016012968 A BR112016012968 A BR 112016012968A BR 112016012968 A2 BR112016012968 A2 BR 112016012968A2
Authority
BR
Brazil
Prior art keywords
aging
methods
compositions
conditions associated
treatment
Prior art date
Application number
BR112016012968A
Other languages
English (en)
Inventor
Wyss-Coray Anton
M Castellano Joseph
MIDDELDORP Jinte
A Villeda Saul
S Angst Martin
Luo Jian
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR112016012968A2 publication Critical patent/BR112016012968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA O TRATAMENTO DE CONDIÇÕES ASSOCIADAS COM O ENVELHECIMENTO. Métodos e composições são fornecidos para o tratamento de um indivíduo quanto às condições associadas com o envelhecimento, por exemplo, as condições de disfunção cognitiva. Os aspectos dos métodos incluem a administração de um produto derivado do sangue compreendendo plasma juvenil a um indivíduo com sua necessidade, por exemplo, um indivíduo que sofre ou em risco de desenvolver a condição associada com o envelhecimento, por exemplo, a disfunção cognitiva associado ao envelhecimento. Também são fornecidos composições e seus kits que encontram uso na prática dos métodos da invenção.
BR112016012968A 2013-12-09 2014-12-05 Métodos e composições para o tratamento de condições associadas com o envelhecimento BR112016012968A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913812P 2013-12-09 2013-12-09
US201462069044P 2014-10-27 2014-10-27
PCT/US2014/068897 WO2015088915A1 (en) 2013-12-09 2014-12-05 Methods and compositions for treating aging-associated conditions

Publications (1)

Publication Number Publication Date
BR112016012968A2 true BR112016012968A2 (pt) 2017-08-08

Family

ID=53270052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012968A BR112016012968A2 (pt) 2013-12-09 2014-12-05 Métodos e composições para o tratamento de condições associadas com o envelhecimento

Country Status (13)

Country Link
US (2) US10688130B2 (pt)
EP (1) EP3079708A4 (pt)
JP (2) JP6667438B2 (pt)
KR (2) KR102155857B1 (pt)
CN (1) CN106163530A (pt)
AU (1) AU2014364182B2 (pt)
BR (1) BR112016012968A2 (pt)
CA (1) CA2933440A1 (pt)
EA (1) EA035336B1 (pt)
IL (1) IL246023B (pt)
MX (1) MX2016007492A (pt)
NZ (1) NZ720949A (pt)
WO (1) WO2015088915A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
US11007230B1 (en) * 2015-08-28 2021-05-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
US11628190B2 (en) * 2015-08-28 2023-04-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
EP4353320A3 (en) 2016-04-28 2024-05-15 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
EP3252452A1 (en) * 2016-05-25 2017-12-06 The Board of Trustees of the Leland Stanford Junior University Method for imaging and analysis of a biological specimen
US20210290835A1 (en) * 2016-08-05 2021-09-23 Jay Yadav Plasma banking to mitigate aging
MD3484502T2 (ro) * 2016-08-18 2022-01-31 Alkahest Inc Fracțiuni de plasmă sanguină utilizate pentru tratamentul tulburărilor cognitive asociate cu îmbătrânirea
WO2018071869A1 (en) * 2016-10-14 2018-04-19 The Regents Of The University Of California Heterochronic blood exchange as a modality to influence myogenesis, neurogenesis, and liver regeneration
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CN106581063B (zh) * 2016-12-29 2018-11-06 北京豪思生物科技有限公司 一种用于增强记忆力的血浆分离物及其制备方法和应用
CN106581062B (zh) * 2016-12-29 2020-09-18 江苏豪思睦可生物科技有限公司 一种用于改善记忆力的混合物及其制备方法和应用
MA48480A (fr) 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
ES2690178A1 (es) 2017-05-18 2018-11-19 Apc Europe Slu Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia
WO2020016543A2 (en) * 2018-03-13 2020-01-23 Nuchido Limited Method of treatment
EP3870190A4 (en) 2018-10-26 2022-09-07 Alkahest, Inc. USE OF PLASMA AND PLASMA FRACTIONS TO REDUCE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CA3151943A1 (en) 2019-11-04 2021-05-14 Viktoria Kheifets Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
CA3156906A1 (en) 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US20220233587A1 (en) * 2021-01-06 2022-07-28 Yuvan Research, Inc. Anti-aging compositions and uses thereof
CN113081079B (zh) * 2021-03-30 2022-04-22 中国科学院生态环境研究中心 血桥限位器
US20240033279A1 (en) * 2022-07-06 2024-02-01 Yuvan Research, Inc. Rna-enriched anti-aging compositions and uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
DE3887114D1 (de) 1987-12-11 1994-02-24 Akzo Nv Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption.
ATE219776T1 (de) 1989-03-21 2002-07-15 Us Secretary United States Dep Matrizenmetalloproteinase-inhibitor-peptide
US5240614A (en) 1992-01-10 1993-08-31 Baxter International Inc. Process for removing unwanted materials from fluids and for producing biological products
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
GB9607287D0 (en) 1996-04-09 1996-06-12 British Biotech Pharm Diagnosis method
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US20020159995A1 (en) 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
AUPR748501A0 (en) 2001-09-04 2001-09-27 Life Therapeutics Limited Renal dialysis
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
DE69942282D1 (de) 1999-01-22 2010-06-02 Dow Global Technologies Inc Oberflächenverändertes divinylbenzenharz mit hämokompatibler beschichtung
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0015761D0 (en) 2000-06-27 2000-08-16 Univ Bristol Polypeptide
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US20030139332A1 (en) 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
EP1394549A1 (en) 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarkers for diagnosing Alzheimer's disease
ES2347924T3 (es) 2002-08-23 2010-11-25 Bayer Schering Pharma Aktiengesellschaft Biomarcadores polipeptidicos para diagnosticar enfermedad de alzheimer.
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20050244448A1 (en) 2002-10-14 2005-11-03 The Board Of Trustees Of The Leland Stanford Jr. University Diagnosis and treatment of disorders of collagen and elastin metabolism
US20040120937A1 (en) * 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
JP2006516252A (ja) 2002-12-27 2006-06-29 アンジオテック インターナショナル アクツィエン ゲゼルシャフト コラーゲンおよびｍｍｐｉを用いる組成物および方法
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
GB0305133D0 (en) * 2003-03-06 2003-04-09 Sinvent As Product
AU2004224807A1 (en) 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
EP1622577A4 (en) 2003-04-17 2007-09-26 Univ Leland Stanford Junior PREVENTION OF DEFICIT NEUROGENESIS DISORDERS WITH ANTI-INFLAMMATORY AGENTS
CN1832756A (zh) 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法
EP2211183B1 (en) 2003-11-19 2013-03-06 Satoris, Inc. Method for diagnosis and monitoring of Alzheimer's disease
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2005106492A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2006009179A1 (ja) 2004-07-23 2006-01-26 Kaneka Corporation 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法
US20090209615A1 (en) 2004-09-27 2009-08-20 Stuart Lipton Inhibitors of matrix metalloproteinases to treat neurological disorders
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006102170A2 (en) 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
US20100062471A1 (en) 2005-09-29 2010-03-11 Ppd Biomarker Discovery Sciences Llc Biomarkers for Multiple Sclerosis and Methods of Use Thereof
WO2007059135A2 (en) 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
WO2007062376A2 (en) 2005-11-21 2007-05-31 Florida Atlantic University Selective inhibition of matrix metalloproteinases
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
US8828977B2 (en) 2006-02-16 2014-09-09 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
EP2030025A2 (en) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8211310B2 (en) 2006-11-20 2012-07-03 Cytosorbents, Inc. Size-selective polymer system
WO2009008928A2 (en) 2007-04-13 2009-01-15 Stemnion, Inc. Methods for treating nervous system injury and disease
GB0710522D0 (en) 2007-06-01 2007-07-11 Royal Veterinary College The Drug delivery system comprising matrix metalloproteinase inhibitors
BRPI0815551A2 (pt) * 2007-08-15 2015-02-18 Univ South Florida Tratamento através de hucbc de doença beta-amiloide
WO2009051660A2 (en) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Compounds for activating tgf-beta signaling
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100015235A1 (en) 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
EP2216060B2 (en) 2007-12-06 2021-03-17 Asahi Kasei Medical Co., Ltd. Porous hollow fiber membrane for blood treatment
WO2010017443A2 (en) 2008-08-07 2010-02-11 Da Zen Group, Llc Anti-beta-2-microglobulin agents and the use thereof
EP2341138B1 (en) 2008-10-09 2017-11-22 Oriental Yeast Co., Ltd. FUSION PROTEIN COMPOSED OF MATRIX METALLOPROTEINASE-2 INHIBITOR PEPTIDE DERIVED FROM AMYLOID-beta PRECURSOR PROTEIN AND TISSUE INHIBITOR OF METALLOPROTEINASE-2
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
US8778616B2 (en) 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20130040844A1 (en) * 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
SI2566517T1 (sl) 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US9782457B2 (en) 2011-10-07 2017-10-10 Tissue Repair Company Flowable formulations for tissue repair and regeneration
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
WO2013063086A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
WO2013122950A1 (en) 2012-02-13 2013-08-22 Wuyi Kong Nprcps, pfdncs and uses thereof
IN2014MN02089A (pt) * 2012-03-20 2015-09-11 Einstein Coll Med
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9512052B2 (en) 2012-10-29 2016-12-06 China Petroleum & Chemical Corporation Adsorption desulfurization process for hydrocarbons and a reaction apparatus therefor
EP3074525A4 (en) 2013-11-26 2017-08-23 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
AU2015247542A1 (en) 2014-04-16 2016-11-24 Blood Systems Research Institute Method and composition for conferring neuroprotection
KR20180030965A (ko) 2015-05-18 2018-03-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화 관련 장애를 치료하기 위한 방법 및 조성물
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
AU2014364182B2 (en) 2019-03-07
MX2016007492A (es) 2017-03-06
IL246023B (en) 2019-11-28
EA201690969A1 (ru) 2016-09-30
US10688130B2 (en) 2020-06-23
KR20160086965A (ko) 2016-07-20
US20150157664A1 (en) 2015-06-11
KR20200108372A (ko) 2020-09-17
AU2014364182A1 (en) 2016-06-30
EA035336B1 (ru) 2020-05-29
CN106163530A (zh) 2016-11-23
US20200352994A1 (en) 2020-11-12
IL246023A0 (en) 2016-07-31
JP6667438B2 (ja) 2020-03-18
EP3079708A4 (en) 2017-08-30
NZ720949A (en) 2019-03-29
EP3079708A1 (en) 2016-10-19
JP2019194249A (ja) 2019-11-07
KR102351604B1 (ko) 2022-01-18
JP2016539992A (ja) 2016-12-22
KR102155857B1 (ko) 2020-09-15
JP6931678B2 (ja) 2021-09-08
WO2015088915A1 (en) 2015-06-18
CA2933440A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
BR112016012968A2 (pt) Métodos e composições para o tratamento de condições associadas com o envelhecimento
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
EA201590388A1 (ru) Способы лечения таупатии
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
EA201691134A1 (ru) Новые ингибиторы глутаминазы
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112014020826A2 (pt) moduladores e métodos de uso
CY1120535T1 (el) Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017007025A2 (pt) sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais
BR112016002317A8 (pt) Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos
BR112015024625A2 (pt) composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements